International Stem Cell Corporation Signs Letter of Intent with BioTime, and Embryome Sciences, Inc. to Provide Unique Human Stem Cell Lines for Research Use

Published: Apr 03, 2008

OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO) and its wholly-owned subsidiary Lifeline Cell Technology (Lifeline) have signed a letter of intent with BioTime, Inc., (OTCBB:BTIM) (Emeryville, CA) and BioTime’s wholly-owned subsidiary Embryome Sciences, Inc., to jointly produce and distribute hundreds of new standardized human and animal stem cell lines, along with corresponding data and reagents. The mutual goal is to provide unique research tools for scientists seeking cures for human disease through regenerative medicine and pharmaceutical drug discovery.

Back to news